Navigation Links
GUMC's Lombardi Hosts Symposium Exploring Future of Cancer Research and Personalized Medicine
Date:2/12/2010

WASHINGTON, Feb. 12 /PRNewswire-USNewswire/ -- The Georgetown Lombardi Comprehensive Cancer Center hosts a symposium exploring the future of cancer research on Feb. 17th at Georgetown University Medical Center (GUMC).  Sponsored by the Ruesch Center for the Cure of Gastrointestinal Cancers, the two-part symposium, "Fighting a Smarter War Against Cancer: Personalized Medicine & the Cure for Cancer," will offer a focus on personalized medicine by bringing together experts in academia, industry and advocacy.  The two-part symposium from 2:00 to 6:30 p.m. is open to the public.  

The first part of the symposium discusses the scientific basis for personalized medicine, while the second brings in voices from pharmaceutical industries, bioethics and patient advocacy. Guest speakers include Carolyn "Bo" Aldige, president and founder of Prevent Cancer Foundation; Mace Rothenberg, MD, senior vice president of Pfizer Oncology; Carol Taylor, Ph.D., MSN, director of the Center for Clinical Bioethics at GUMC; and the Hon. W.J. (Billy) Tauzin, president and CEO of Pharmaceutical Research and Manufacturers of America (PhRMA).  Rothenberg will deliver the annual Thomas R. Schafer Memorial Lecture in Pancreatic and Gastrointestinal Cancer.

The symposium builds on the philosophy of the director of the Ruesch Center, John L. Marshall, MD, a leading gastrointestinal oncologist who advocates re-invigorating the war on cancer by focusing research on a cure, not incremental improvements.  He recently wrote about his views on cancer research in the

SOURCE Georgetown University Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lombardis Shields leads special journal focused on tobacco research
2. Medical University of South Carolina Automates Grants Allocation Process with Lombardi Business Process Management Software
3. Georgetowns Lombardi Comprehensive Cancer Center and the Capital Breast Care Center Pound the Pavement to Save Lives
4. Lombardi Cancer Center and the Capital Breast Care Center awarded $750,000 from the AVON Foundation
5. V. Craig Jordan, Internationally Renowned Breast Cancer Scientist, Joins Georgetowns Lombardi Comprehensive Cancer Center
6. NICHD Deploying Lombardi Business Process Management (BPM) Suite
7. Lombardi Comprehensive Cancer Center publishes manual for childhood cancer survivors
8. Lombardi Cancer Centers Toretsky awarded prestigious Burroughs Wellcome Fund Award
9. Centene Corporation Hosts Medical Management Systems Update in New York City
10. Arthur M. Blank Family Foundation Hosts Author of Last Child in the Woods: Saving our Children from Nature-Deficit Disorder
11. BayCare Hosts Public Events to Celebrate American Heart Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on ... review today examining the current state of knowledge of ... for improved global surveillance strategies to combat the emergence ... Ebola in West Africa that has claimed the lives ... Liberia. According to the World Health Organization (WHO), ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... the World; First Centers to Open ... France and China, Kenneth P. Moritsugu, M.D., Former Acting Surgeon General, Appointed to ... Lead Global ... today announced the establishment of the Johnson &,Johnson Diabetes Institute (JJDI) to transform diabetes ...
... IT Services Leader Will Provide Systems Operations, ... Military Health System Computing Environment, ARLINGTON, ... leading global,provider of information management and business ... awarded the Military Health System,Executive Information and ...
... MedPredict Market Research,a global provider of pharmaceutical ... report providing critical strategic insight,for pharma and biotech ... anxiety and,depression therapies. In this report, entitled ... physician experts from North America and Europe,discuss the ...
... and Oncology is pleased to announce that Stefanie LaRue of ... Circle Award winner. Ms. LaRue will be presented with her ... 2007, at 8:00 a.m. at the Los Angeles Convention Center ... 28 through November 1 in Los Angeles., The Survivor Circle ...
... existing regimen may help, researchers say , TUESDAY, Oct. ... as an added therapy, the epilepsy drug lamotrigine is ... , The 239 participants, aged 13 and older, were ... They were already taking one or two medications, but ...
... For the seventh,consecutive year West Coast Bank will partner ... the Heart of Doernbecher Auction, which,has raised over $2.5 ... tie event will be held at Portland Art Museum, ... Bank,s Executive Vice President of Commercial Banking Xandra,McKeown serves ...
Cached Medicine News:Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 2Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 3Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 4Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:New Report Provides Insight Into Developments in the Market for Anxiety and Depression Therapies 2Health News:LA breast cancer activist honored with Survivor Circle Award 2Health News:LA breast cancer activist honored with Survivor Circle Award 3Health News:Lamotrigine May Reduce Epilepsy Seizures 2Health News:West Coast Bank Will Sponsor the Heart of Doernbecher Auction at the Portland Art Museum, October 20, 2007 2
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
...
Medicine Products: